GAIN THERAPEUTICS INC (GANX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$1.11-3.48%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
QuarterlyIQ Insights · GANX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 2.1% |
| Our one-year growth estimate | diamond | 1.3% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 0.8 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name is a smaller-cap name (higher miss base rate) and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-11-04 · Compared with 66 industry peers
GANX — President transition
Dated 2026-10-28
Vice President, Finance — Jeanette Weidner: The filing discloses the external appointment of a new Vice President, Finance who will also serve as the principal financial and accounting officer.
Why it matters: Final extension data can show if stable symptoms and biomarker changes last. Management planned to share results in October.
Supportive ifThe October presentation shows stable or better MDS-UPDRS scores through Day 360. Results are stronger in patients with high baseline CSF GluSph.
Worry ifThe presentation shows worsening MDS-UPDRS scores through Day 360, or does not back the earlier response in patients with high GluSph.
Why it matters: Cash fell to $13.1 million by June 30, 2026. The next report can show whether cash use is changing as the Phase 2 study advances.
Worry ifThe November 11 report shows cash below $13.1 million and quarterly net loss above the Q2 level of $0.11 per share.
Less concerning ifThe November 11 report shows cash at or above $13.1 million, or a quarterly net loss below $0.11 per share.
Why it matters: A named first use would show the next pipeline program is moving toward human testing. Management tied the choice to year-end 2026.
Supportive ifGain names GT-04686’s first target indication by year-end 2026. It also reports progress on studies needed for an IND.
Worry ifThe year ends without a named indication, or Gain says work toward studies needed for an IND has stalled.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$225 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $764 loss on $10,000 · 7.6% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $7,344 loss on $10,000 · 73.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.